Paloma Partners’s Heron Therapeutics HRTX Stock Holding History

Paloma Partners’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-11,229	Closed	-$208K	–	2308
2019 Q3	$208K	Buy	+11,229	New	+$207K	﹤0.01%	1735
2018 Q1	–	Sell	-12,769	Closed	-$231K	–	2077
2017 Q4	$231K	Buy	+12,769	New	+$208K	﹤0.01%	1662
2016 Q1	–	Sell	-11,845	Closed	-$316K	–	1937
2015 Q4	$316K	Buy	+11,845	New	+$317K	0.01%	1294

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Paloma Partners's HRTX Position: Q4 2019 in Review

Paloma Partners sold out of Heron Therapeutics (HRTX) in Q4 2019, closing a stake of 11,229 shares — an estimated $208K sold.

Paloma Partners first reported a position in HRTX in Q4 2015 and held it in 3 quarters. The position peaked at $316K in Q4 2015. 199 funds tracked by Wall St. Rank hold HRTX as of Q4 2019.

Paloma Partners reported no remaining Heron Therapeutics position as of Q4 2019 after selling out during the quarter.
Paloma Partners sold 11,229 Heron Therapeutics shares in Q4 2019, an estimated $208K.
Paloma Partners first reported a position in Heron Therapeutics in Q4 2015 and held it in 3 quarters.
Paloma Partners's Heron Therapeutics position peaked at $316K in Q4 2015.
199 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2019.

Based on Paloma Partners's 13F filing for Q4 2019, filed 14 Feb 2020.